Argenx SE (NASDAQ: ARGX) shares surged 15.15% in pre-market trading on Thursday following the release of its outstanding second-quarter financial results. The biopharmaceutical company significantly surpassed analyst expectations, demonstrating robust growth and financial performance.
For Q2 2025, Argenx reported earnings per share (EPS) of $3.74, handily beating the analyst consensus estimate of $2.77 by 34.87%. This represents a remarkable 731.11% increase from the $0.45 per share reported in the same period last year. The company's quarterly sales also impressed, coming in at $967.19 million, surpassing the analyst consensus estimate of $868.16 million by 11.41%. This figure marks a substantial 97.62% year-over-year increase from $489.43 million in the previous year's quarter.
The strong financial performance underscores Argenx's growing market position and the success of its product portfolio. With both earnings and revenue significantly exceeding expectations, investors are showing increased confidence in the company's future prospects, as reflected in the pre-market stock surge. This positive momentum could potentially carry over into regular trading hours, as the market digests the implications of Argenx's impressive quarterly results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.